Literature DB >> 15723230

Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis.

Danuta Marona-Lewicka1, Ronald A Thisted, David E Nichols.   

Abstract

RATIONALE: The effect of LSD in humans has been described as occurring in two temporal phases. The behavioral effects in rats also occur in two temporal phases: an initial suppression of exploration followed by increased locomotor activity.
OBJECTIVES: We decided to investigate this phenomenon from the perspective that the pharmacology might have relevance to the neurochemical mechanisms underlying psychosis.
METHODS: Twenty-five male Sprague-Dawley rats were trained to discriminate LSD (186 nmol/kg, 0.08 mg/kg, i.p.) with a 30-min preinjection time (LSD-30, N=12) and LSD (372 nmol/kg, 0.16 mg/kg, i.p.) with a 90-min preinjection time (LSD-90, N=13) from saline, using a two-lever, food-reinforced operant conditioning task.
RESULTS: LSD (186 or 372 nmol/kg, 0.08 or 0.16 mg/kg) given 30 min prior to training produced a cue that was completely antagonized by 5-HT2A antagonists and lasted no longer than 1 h. LSD (372 nmol/kg, 0.16 mg/kg) injected 90 min before training produced a cue that was not fully blocked by 5-HT2A antagonists, but instead was significantly inhibited by haloperidol. In these rats, substitution no longer occurred with the 5-HT2 agonists DOI or LSD (30 min preinjection), but full substitution was obtained with the D2 agonists apomorphine, N-propyldihydrexidine, and quinelorane.
CONCLUSION: The discriminative stimulus effect of LSD in rats occurs in two phases, and these studies provide evidence that the later temporal phase is mediated by D2 dopamine receptor stimulation. A second temporal phase that involves dopaminergic pathways would be consistent with the widespread belief that excessive dopaminergic activity may be an underlying cause of paranoid psychosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15723230     DOI: 10.1007/s00213-005-2183-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  43 in total

Review 1.  Serotonergic receptor subtypes and hallucinogen-induced stimulus control.

Authors:  J C Winter; D J Fiorella; D M Timineri; R A Filipink; S E Helsley; R A Rabin
Journal:  Pharmacol Biochem Behav       Date:  1999-10       Impact factor: 3.533

2.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

3.  Hallucinogenic drug research--if so, so what? Symposium summary and commentary.

Authors:  D X Freedman
Journal:  Pharmacol Biochem Behav       Date:  1986-02       Impact factor: 3.533

4.  Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase.

Authors:  David M Mottola; Jason D Kilts; Mechelle M Lewis; Hilary S Connery; Q David Walker; Sara R Jones; Raymond G Booth; Deborah K Hyslop; Monford Piercey; R Mark Wightman; Cindy P Lawler; David E Nichols; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

5.  5-HT2A/2C receptor agonists potentiate the discriminative cue of (+)-amphetamine in the rat.

Authors:  D Marona-Lewicka; D E Nichols
Journal:  Neuropharmacology       Date:  1997-10       Impact factor: 5.250

6.  Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists.

Authors:  R A Glennon; R Young; J A Rosecrans
Journal:  Eur J Pharmacol       Date:  1983-07-22       Impact factor: 4.432

7.  Dopaminergic and serotonergic mediation of the discriminable effects of ergot alkaloids.

Authors:  A M Holohean; F J White; J B Appel
Journal:  Eur J Pharmacol       Date:  1982-07-30       Impact factor: 4.432

8.  Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5-HT2- versus 5-HT1C-selective antagonist.

Authors:  A M Ismaiel; J De Los Angeles; M Teitler; S Ingher; R A Glennon
Journal:  J Med Chem       Date:  1993-08-20       Impact factor: 7.446

9.  Comparative discriminative stimulus effects of 5-methoxy-N,N-dimethyltryptamine and LSD.

Authors:  R Young; J A Rosecrans; R A Glennon
Journal:  Life Sci       Date:  1982-06-14       Impact factor: 5.037

10.  Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents.

Authors:  R A Glennon; M Titeler; J D McKenney
Journal:  Life Sci       Date:  1984-12-17       Impact factor: 5.037

View more
  36 in total

Review 1.  Early preclinical studies of discriminable sedative and hallucinogenic drug effects.

Authors:  Herbert Barry; James B Appel
Journal:  Psychopharmacology (Berl)       Date:  2008-08-20       Impact factor: 4.530

2.  Potential serotonin 5-HT(1A) and dopamine D(4) receptor modulation of the discriminative stimulus effects of amphetamine in rats.

Authors:  Danuta Marona-Lewicka; David E Nichols
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

3.  Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers.

Authors:  Anna Bravermanová; Michaela Viktorinová; Filip Tylš; Tomáš Novák; Renáta Androvičová; Jakub Korčák; Jiří Horáček; Marie Balíková; Inga Griškova-Bulanova; Dominika Danielová; Přemysl Vlček; Pavel Mohr; Martin Brunovský; Vlastimil Koudelka; Tomáš Páleníček
Journal:  Psychopharmacology (Berl)       Date:  2018-01-05       Impact factor: 4.530

4.  An animal model of schizophrenia based on chronic LSD administration: old idea, new results.

Authors:  Danuta Marona-Lewicka; Charles D Nichols; David E Nichols
Journal:  Neuropharmacology       Date:  2011-02-23       Impact factor: 5.250

5.  Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.

Authors:  Clinton E Canal
Journal:  Handb Exp Pharmacol       Date:  2018

Review 6.  Preclinical models of antipsychotic drug action.

Authors:  José L Moreno; Javier González-Maeso
Journal:  Int J Neuropsychopharmacol       Date:  2013-06-10       Impact factor: 5.176

7.  Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor.

Authors:  Franz X Vollenweider; Alan Anticevic; Katrin H Preller; Joshua B Burt; Jie Lisa Ji; Charles H Schleifer; Brendan D Adkinson; Philipp Stämpfli; Erich Seifritz; Grega Repovs; John H Krystal; John D Murray
Journal:  Elife       Date:  2018-10-25       Impact factor: 8.140

8.  Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes.

Authors:  Bruce E Blough; Antonio Landavazo; Ann M Decker; John S Partilla; Michael H Baumann; Richard B Rothman
Journal:  Psychopharmacology (Berl)       Date:  2014-05-07       Impact factor: 4.530

9.  Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats.

Authors:  Tomáš Páleníček; Michaela Fujáková; Martin Brunovský; Jiří Horáček; Ingmar Gorman; Marie Balíková; Lukáš Rambousek; Kamila Syslová; Petr Kačer; Petr Zach; Věra Bubeníková-Valešová; Filip Tylš; Anna Kubešová; Jana Puskarčíková; Cyril Höschl
Journal:  Psychopharmacology (Berl)       Date:  2012-07-29       Impact factor: 4.530

Review 10.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Authors:  Adam L Halberstadt
Journal:  Behav Brain Res       Date:  2014-07-15       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.